ArticleBioMed research international2026
Evaluation of the Hepatoprotective Efficacy of Bee Pollen and Bee Pollen Ethanolic Extract-Loaded Solid Lipid Nanoparticles Against Lead Acetate-Induced Hepatotoxicity in Male Wistar Rats.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Evaluation of the Hepatoprotective Efficacy of Bee Pollen and Bee Pollen Ethanolic Extract-Loaded Solid Lipid Nanoparticles Against Lead Acetate-Induced Hepatotoxicity in Male Wistar Rats.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bee pollen, a natural product rich in polyphenols, exhibits remarkable antioxidant, anti-inflammatory, and hepatoprotective properties. Aim: This study was aimed at evaluating the hepatoprotective effects of solid lipid nanoparticles (SLNs) loaded with bee pollen. Materials and Methods: SLNs were formulated and optimized by varying surfactant ratios and lipid contents at two different temperatures. Results and Discussion: The optimized bee pollen SLNs demonstrated a particle size of 118.6 nm, a PdI of 0.35, a zeta potential of -22.6 mV, and an entrapment efficiency of 92.7%. The in vitro release study showed minimal release during the initial 120 min, followed by a continuous increase up to 48 h, indicating a sustained and prolonged release profile. Both bee pollen and bee pollen ethanolic extract-loaded SLNs exhibited significant cytoprotective effects against lead-induced cytotoxicity in HepG2 cells. In vivo studies revealed that treatment with bee pollen and especially bee pollen SLNs substantially ameliorated lead-induced hepatic injury. Treatment notably reduced serum levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, malondialdehyde, and nitric oxide. Additionally, it enhanced the activity of glutathione peroxidase, catalase, superoxide dismutase, and total antioxidant capacity, as well as levels of total thiol, reduced glutathione, and liver tissue proteins. Histopathological analysis further confirmed that treatment, particularly with bee pollen SLNs, significantly improved lead-induced hepatic structural damage. Conclusion: These findings confirm that bee pollen, and more prominently its SLN formulation, possesses strong hepatoprotective potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.